InterveXion to Present IXT-m200 Program and Phase 2 STAMPOUT Study Design at Upcoming College on Problems in Drug Dependence Meeting
- IXT-m200 is InterveXion’s lead program in treating methamphetamine abuse - STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users Little Rock, AR – InterveXion Therapeutics, a private...
read moreInterveXion Enrolls First Patient in Phase 2 Study of the Effect of IXT-m200 on Methamphetamine PK and PD
STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users Little Rock, AR – InterveXion announces the enrollment of the first patient in STAMPOUT, the first trial in methamphetamine users of the...
read moreInterveXion Licenses Asian Rights to Novel Anti-Methamphetamine Antibody to Ascent Therapeutics
Addresses Major Global Unmet Medical Need in Addiction Therapy Lead Asset, IXT-m200, has Received US FDA Fast-Track Designation IXT-m200 Advancing into Phase 2 Clinical POC Study in 1H18 Parallel Phase 3-Enabling Multiple Dose Clinical Study Initiating in 1H18 Little...
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.
InterveXion to Present IXT-m200 Program and Phase 2 STAMPOUT Study Design at Upcoming College on Problems in Drug Dependence Meeting
- IXT-m200 is InterveXion’s lead program in treating methamphetamine abuse - STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users Little Rock, AR – InterveXion Therapeutics, a private...
read moreInterveXion Enrolls First Patient in Phase 2 Study of the Effect of IXT-m200 on Methamphetamine PK and PD
STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users Little Rock, AR – InterveXion announces the enrollment of the first patient in STAMPOUT, the first trial in methamphetamine users of the...
read moreInterveXion Licenses Asian Rights to Novel Anti-Methamphetamine Antibody to Ascent Therapeutics
Addresses Major Global Unmet Medical Need in Addiction Therapy Lead Asset, IXT-m200, has Received US FDA Fast-Track Designation IXT-m200 Advancing into Phase 2 Clinical POC Study in 1H18 Parallel Phase 3-Enabling Multiple Dose Clinical Study Initiating in 1H18 Little...
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.